TailorMed

Every healthcare innovation eventually runs into the same uncomfortable question: what happens after the prescription is written? For millions of patients across the United States, the answer has less to do with medicine and more to do with money. High out-of-pocket costs, fragmented financial assistance programs, insurance complexity, and administrative friction often become the real barriers to treatment. TailorMed exists to solve that problem.

Founded in the mid-2010s by CEO Srulik Dvorsky and CTO Adam Siton, TailorMed has evolved into one of the country's largest medication affordability networks. Headquartered in New York City with significant operations in Tel Aviv, the company serves hospitals, health systems, pharmacies, life sciences companies, and, ultimately, the patients navigating one of healthcare's most overlooked challenges: paying for care after the diagnosis has already been made. That mission matters because healthcare's affordability problem is no longer a side story. It is becoming one of the defining operational challenges for providers, pharmaceutical companies, and policymakers alike.

About TailorMed

TailorMed describes its mission as removing barriers along the medication journey. Instead of treating affordability as a disconnected administrative task, TailorMed connects providers, pharmacies, pharmaceutical manufacturers, and patients through a technology platform designed to improve access, affordability, and medication adherence. The company is positioning itself not simply as a financial navigation vendor, but as infrastructure connecting participants across the post-prescription experience.

The company's platform has expanded steadily over the years. TailorMed Complete combines automation with experienced financial navigators for organizations seeking a managed service. TailorMed Amplify embeds manufacturer support programs directly into provider and pharmacy workflows, while TailorMed Connect extends that reach to patients through a self-service digital experience. That progression moves TailorMed beyond isolated reimbursement challenges toward a broader Medication Success Platform, where financial decisions often determine whether treatment begins at all.

Why TailorMed Matters Right Now

Healthcare has never lacked clinical innovation, but it has often lacked operational coordination. Patients regularly encounter thousands of assistance programs spread across manufacturers, charitable foundations, and government agencies, and many qualify for financial support but never receive it because the system remains fragmented, manual, and difficult to navigate. TailorMed's thesis is that affordability should become part of the routine clinical workflow rather than a separate administrative exercise.

Scale reinforces that argument. According to the company's public materials, TailorMed supports more than 75 million patients, has processed more than 335 million prescriptions, and operates across more than 950 hospitals, 4,700 clinics, and 3,100 pharmacies. Those figures suggest the platform has moved beyond early-stage experimentation into nationally significant healthcare infrastructure, where every additional provider, pharmacy, and manufacturer increases the value of the broader network.

The Problem TailorMed Is Solving

Healthcare discussions often celebrate breakthrough therapies while overlooking the distance between approval and actual patient access. Financial toxicity has become an increasingly recognized clinical issue, with rising deductibles, specialty drug pricing, insurance complexity, and administrative delays frequently preventing patients from starting prescribed therapies or continuing treatment over time. TailorMed addresses that gap through automation, predictive matching, workflow integration, and financial navigation services designed to identify available assistance before financial barriers derail care.

Rather than replacing healthcare providers, the platform aims to reduce the operational burden placed on them. That distinction deserves attention because hospitals face pressure from multiple directions simultaneously. Patients struggle with affordability while providers contend with uncompensated care, reimbursement complexity, and growing administrative workloads. Solutions that improve both patient outcomes and provider operations naturally attract institutional interest.

Leadership and Strategic Growth

TailorMed's leadership reflects a combination of healthcare expertise, engineering experience, and operational discipline. Srulik Dvorsky brings both medical technology experience and personal insight into the realities families face while navigating serious illness, while Adam Siton leads the company's technology strategy as CTO. Building healthcare infrastructure requires more than software development; it demands operational credibility across providers, payers, life sciences organizations, and patient support ecosystems.

The broader executive team includes COO Gideon Jagermann, CFO Lior-Zvi Danziger, Head of Product Ayelet Gvirsman, Vice President of Marketing Jen Martin, Vice President of Strategy and Corporate Development Netalie Nadivi, Vice President of Sales Jill Klasko, Vice President of Customers Kimberly Pellish, Vice President of Service Operations Dominique Phillips, Vice President of Research and Development Dina Fine, Vice President of Strategic Growth (Life Sciences) Gal Nevo, Vice President of People Noa Inbar, and Vice President of Program Management and Implementation Services Michal Walt. That mix of finance, product, R&D, commercial, customer, and life sciences leadership is part of the story because TailorMed's category requires execution across software, healthcare operations, and ecosystem partnerships simultaneously.

Funding, Partnerships, and Market Validation

TailorMed has attracted backing from investors with deep healthcare expertise rather than purely financial interests. Its $40M financing, announced in November 2024, was led by Windham Capital Partners, with participation from Samsung NEXT, Providence Ventures, Citi Impact Fund, BrightEdge, OSF Ventures, UnityPoint Health Ventures, and other healthcare-focused organizations. Many of those investors also represent strategic relationships within the healthcare ecosystem, creating alignment among capital, customers, and long-term distribution.

The company has also established relationships with organizations including Providence Health, Yale New Haven Health, Advocate Aurora Health, Intermountain Health, and McKesson. Those partnerships indicate that TailorMed's value proposition extends beyond software deployment into operational integration across healthcare delivery. For digital health companies, that kind of validation matters because customers are not simply buying software; they are trusting a platform with workflows that influence patient access and provider economics.

Why Hiring Momentum Matters

TailorMed continues hiring across engineering, AI, product management, operations, commercial teams, and financial navigation roles in both the United States and Israel, with current openings listed on its careers page. Viewed through a market intelligence lens, that hiring activity signals something larger than organizational growth. Healthcare technology increasingly depends on interdisciplinary teams capable of combining enterprise software, artificial intelligence, clinical workflows, regulatory expertise, and customer operations.

For experienced operators, engineers, and healthcare professionals, TailorMed represents a case study in how modern digital health companies are evolving from point solutions into platform businesses. Hiring across product, AI, engineering, operations, and commercial roles suggests the company is scaling the machinery around customer demand rather than adding headcount for appearances. In this category, hiring momentum is not a recruiting slogan; it is a signal that medication access is becoming a critical infrastructure challenge.

The Bigger Industry Shift

The next decade of healthcare innovation may not be defined solely by discovering new therapies. It may be defined by ensuring existing therapies actually reach the patients who need them, changing how investors evaluate digital health, how providers select technology partners, and how pharmaceutical companies measure patient support. TailorMed's transition toward a Medication Success Platform reflects this broader market shift, where access, affordability, adherence, and ongoing patient engagement are increasingly interconnected operational challenges rather than separate categories.

Whether TailorMed ultimately becomes the dominant operating layer for the medication journey remains to be seen. What is already clear is that healthcare's biggest obstacles are no longer confined to laboratories or clinical trials; they often begin the moment a prescription leaves the physician's desk. Companies capable of reducing that friction may prove just as influential as those discovering the next breakthrough treatment because innovation changes lives only when patients can actually access it.